Walleye Capital
NVO

Walleye Capital’s Novo Nordisk NVO Stock Holding History

Walleye Capital’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.3M Buy
578,309
+77,665
+16% +$3.68M 0.09% 174
2025
Q4 		$25.5M Buy
500,644
+356,879
+248% +$18.2M 0.08% 211
2025
Q3 		$7.98M Buy
143,765
+143,737
+513,346% +$8.41M 0.03% 646
2025
Q2 		$1.93K Sell
28
-190,926
-100% -$13M ﹤0.01% 4388
2025
Q1 		$13.3M Buy
190,954
+28,867
+18% +$2.38M 0.06% 320
2024
Q4 		$13.9M Sell
162,087
-89,839
-36% -$9.72M 0.03% 459
2024
Q3 		$30M Buy
251,926
+69,241
+38% +$9.23M 0.06% 217
2024
Q2 		$26.1M Buy
182,685
+78,134
+75% +$10.4M 0.05% 268
2024
Q1 		$13.4M Sell
104,551
-34,065
-25% -$4.06M 0.02% 646
2023
Q4 		$14.3M Sell
138,616
-54,179
-28% -$5.36M 0.03% 499
2023
Q3 		$17.5M Buy
+192,795
New +$17M 0.04% 307

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Walleye Capital's NVO Position: Q1 2026 in Review

Walleye Capital increased its Novo Nordisk (NVO) stake by 16% in Q1 2026, buying an estimated $3.68M and bringing the position to 578,309 shares worth $21.3M. The position accounts for 0.09% of the portfolio, ranked #174.

Walleye Capital first reported a position in NVO in Q3 2023 and has held it in 11 quarters since. The position peaked at $30M in Q3 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Walleye Capital held 578,309 shares of Novo Nordisk worth $21.3M as of Q1 2026.
  • Walleye Capital bought 77,665 Novo Nordisk shares in Q1 2026, an estimated $3.68M.
  • Novo Nordisk made up 0.09% of Walleye Capital's portfolio in Q1 2026, its #174 holding.
  • Walleye Capital first reported a position in Novo Nordisk in Q3 2023 and has held it in 11 quarters since.
  • Walleye Capital's Novo Nordisk position peaked at $30M in Q3 2024.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.